



Institute for Applied Biomedicine

Keeping the Immune System on Track™

Institute for Applied Biomedicine is a 501(c)(3) non-profit research organization dedicated to developing effective, accessible treatments for AIDS and other serious immune system disorders.

We are engaged in early-stage research related to a potential treatment for HIV/AIDS. Our research is focused on changing the way the immune system reacts to HIV, instead of directly attacking the virus.

As part of our research program, the Institute has designed and produced a prototype of a future treatment to prevent the onset of AIDS, which is called Immudel-gp120. This drug design combines the newest advances in cell targeting technology from current cancer research with fundamental research on the immune system.

40 million people around the world have HIV, including almost 1 million people in the U.S.

The Institute is currently running further studies to verify Immudel-gp120's effectiveness. More than a million dollars' testing needs to be done before human testing can begin. Future studies are planned to explore the application of similar technology to other immune system disorders, such as lupus and rheumatoid arthritis.

200 Santa Cruz County residents currently have AIDS, and another 600 have already died from it.

We maximize the effect of every dollar by partnering with other academic and industry groups to take advantage of free and reduced-cost lab work. We maintain very low overhead expenses, and we meet or exceed every standard set by the Better Business Bureau Wise Giving Alliance.

You can help by supporting fundraisers, making donations, joining one of our management and funding committees, or helping with routine work at the office. More than half of our budget is supported by individual people like you.

If you would like more information about the Institute, please visit our website at <http://www.appliedbiomed.org> or call the office at 831 454-9147 to request an information packet.

- 1996 • Founded by UCSC Prof. Frank Andrews, Ph.D.
- 1997 • Scientific peer review meeting at the NIH—Division of AIDS
- 1998 • Lab work begun to create AIDS drug
- 1999 • Immudel-gp120, the new AIDS drug, made for first time in lab
- First study on human white blood cells
- 2000 • Data from pilot safety, efficacy studies released
- 2001 • Production upgrade, major experiments designed
- 2002 • Data: Immudel-gp120 is precise, selective
- 2003 • Work to lower production costs
- 2004 • Lab studies on the strength of drug action and dose size
- "AIDS simulation" study in human blood cells

Since 1996, the Institute has conducted nearly \$500,000 worth of AIDS research.